Zhong Xian, Shen Hong, Mao Jianshan, Zhang Jiawei, Han Weidong
Department of Medical Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
Department of Medical Oncology, Hangzhou Binjiang Hospital, Hangzhou, Zhejiang 310052, P.R. China.
Oncol Lett. 2017 Apr;13(4):2449-2453. doi: 10.3892/ol.2017.5733. Epub 2017 Feb 13.
Colorectal cancer (CRC) is one of the most common types of malignant tumor in the world and occurs through a multi-step process resulting from the accumulation of genetic and epigenetic alterations of the genome. Although the molecular mechanisms of the pathogenesis of CRC remain unclear, the inactivation of tumor suppressor genes (TSGs) through promoter methylation serves an important role. Aberrant methylation is a well-defined marker of CRC. At present, the epigenetic silencing of protocadherin 10 (PCDH10) has been identified as an important TSG with key roles in colorectal carcinogenesis, invasion and metastasis as a frequent and early event. Advances in gene methylation detection in tumor tissues and body fluids have led to the development of non-invasive screening methods for CRC. The present study aimed to review the epigenetic alteration of PCDH10 in CRC development, and the potential of PCDH10 to be a non-invasive biomarker for CRC.
结直肠癌（CRC）是世界上最常见的恶性肿瘤类型之一，其发生是一个多步骤过程，由基因组的遗传和表观遗传改变积累所致。尽管CRC发病机制的分子机制尚不清楚，但通过启动子甲基化使肿瘤抑制基因（TSG）失活起着重要作用。异常甲基化是CRC的一个明确标志物。目前，原钙黏蛋白10（PCDH10）的表观遗传沉默已被确定为一种重要的TSG，在结直肠癌发生、侵袭和转移中作为常见且早期事件发挥关键作用。肿瘤组织和体液中基因甲基化检测技术的进展已促使CRC非侵入性筛查方法的发展。本研究旨在综述PCDH10在CRC发生发展中的表观遗传改变，以及PCDH10作为CRC非侵入性生物标志物的潜力。
